Persons living with HIV/AIDS (PLWHA) frequently use cannabinoids, either recreationally by smoking marijuana or therapeutically (delta-9-tetrahydrocannabinol; Δ9-THC dronabinol). Previously, we demonstrated that chronic Δ9-THC administration decreases early mortality in male simian immunodeficiency virus (SIV)-infected macaques. In this study, we sought to examine whether similar protective effects resulted from chronic cannabinoid administration in SIV-infected female rhesus macaques. Clinical and viral parameters were evaluated in eight female rhesus macaques that received either Δ9-THC (0.18–0.32 mg/kg, intramuscularly, twice daily) or vehicle (VEH) starting 28 days prior to intravenous inoculation with SIVmac251. SIV disease progression was assessed by changes in body weight, mortality, viral levels in plasma and mucosal sites, and lymphocyte subsets. In contrast to our results in male animals, chronic Δ9-THC did not protect SIV-infected female rhesus macaques from early mortality. Markers of SIV disease, including viral load and CD4+/CD8+ ratio, were not altered by Δ9-THC compared to control females; however, females that received chronic Δ9-THC did not gain as much weight as control animals. In addition, Δ9-THC administration increased total CXCR4 expression in both peripheral and duodenal CD4+ and CD8+ T lymphocytes prior to SIV inoculation. Although protection from early mortality was not evident, chronic Δ9-THC did not affect clinical markers of SIV disease progression. The contrasting effects of chronic Δ9-THC in males versus females remain to be explained, but highlight the need for further studies to explore the sex-dependent effects of Δ9-THC and other cannabinoids on the HIV disease course and their implications for virus transmission.
Get full access to this article
View all access options for this article.
References
1.
Substance Abuse and Mental Health Services Administration: Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings NSDUH Series H-46, HHS Publication No. (SMA) 13-4795 ed. Substance Abuse and Mental Health Services Administration, Rockville, MD, 2013.
2.
PrentissD, PowerR, BalmasG, et al.: Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. J Acquir Immune Defic Syndr, 2004; 35(1):38–45.
3.
WoolridgeE, BartonS, SamuelJ, et al.: Cannabis use in HIV for pain and other medical symptoms. J Pain Sympt Manage, 2005; 29(4):358–367.
4.
SohlerNL, WongMD, CunninghamWE, et al.: Type and pattern of illicit drug use and access to health care services for HIV-infected people. AIDS Patient Care STD, 2007; 21(Suppl 1):S68–76.
5.
CofrancescoJJr, ScherzerR, TienPC, et al.: Illicit drug use and HIV treatment outcomes in a US cohort. AIDS, 2008; 22(3):357–365.
6.
MimiagaMJ, ReisnerSL, GrassoC, et al.: Substance use among HIV-infected patients engaged in primary care in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort. Am J Public Health, 2013; 103(8):1457–1467.
7.
DejesusE, RodwickBM, BowersD, et al.: Use of dronabinol improves appetite and reverses weight loss in HIV/AIDS-infected patients. J Int Assoc Physic AIDS Care, 2007; 6(2):95–100.
8.
AggarwalSK, CarterGT, SullivanMD, et al.: Medicinal use of cannabis in the United States: Historical perspectives, current trends, and future directions. J Opioid Manage, 2009; 5(3):153–168.
9.
LutgeEE, GrayA, and SiegfriedN: The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database Syst Rev, 2013; 4:CD005175.
10.
BealJE, OlsonR, LaubensteinL, et al.: Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Sympt Manage, 1995; 10(2):89–97.
11.
BealJE, OlsonR, LefkowitzL, et al.: Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Sympt Manage, 1997; 14(1):7–14.
12.
KuoWH, WilsonTE, WeberKM, et al.: Initiation of regular marijuana use among a cohort of women infected with or at risk for HIV in the Women's Interagency HIV Study (WIHS). AIDS Patient Care STD, 2004; 18(12):702–713.
13.
CarlisleSJ, Marciano-CabralF, StaabA, et al.: Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol, 2002; 2(1):69–82.
14.
Osei-HyiamanD, LiuJ, ZhouL, et al.: Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest, 2008; 118(9):3160–3169.
15.
WinsauerPJ, MolinaPE, AmedeeAM, et al.: Tolerance to chronic delta-9-tetrahydrocannabinol (delta(9)-THC) in rhesus macaques infected with simian immunodeficiency virus. Exp Clin Psychopharmacol, 2011; 19(2):154–172.
16.
MillerAM and StellaN: CB2 receptor-mediated migration of immune cells: It can go either way. Br J Pharmacol, 2008; 153(2):299–308.
17.
RomS and PersidskyY: Cannabinoid receptor 2: Potential role in immunomodulation and neuroinflammation. J Neuroimmune Pharmacol, 2013; 8(3):608–620.
18.
GaliegueS, MaryS, MarchandJ, et al.: Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem/FEBS, 1995; 232(1):54–61.
19.
KleinTW, NewtonC, LarsenK, et al.: The cannabinoid system and immune modulation. J Leukocyte Biol, 2003; 74(4):486–496.
20.
CroxfordJL and YamamuraT: Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases?. J Neuroimmunol, 2005; 166(1–2):3–18.
21.
ParadiseLJ and FriedmanH: Syphilis and drugs of abuse. Adv Exp Med Biol, 1993; 335:81–87.
22.
KleinTW, NewtonC, WidenR, et al.: Delta 9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila. J Pharmacol Exp Therapeut, 1993; 267(2):635–640.
23.
CabralGA and Marciano-CabralF: Cannabinoid-mediated exacerbation of brain infection by opportunistic amebae. J Neuroimmunol, 2004; 147(1–2):127–130.
24.
MishkinEM and CabralGA: delta-9-Tetrahydrocannabinol decreases host resistance to herpes simplex virus type 2 vaginal infection in the B6C3F1 mouse. J Gen Virol, 1985; 66(Pt 12):2539–2549.
25.
BuchweitzJP, KarmausPW, HarkemaJR, et al.: Modulation of airway responses to influenza A/PR/8/34 by delta9-tetrahydrocannabinol in C57BL/6 mice. J Pharmacol Exp Therapeut, 2007; 323(2):675–683.
26.
CabralGA and Dove PettitDA: Drugs and immunity: Cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol, 1998; 83(1–2):116–123.
27.
ReissCS: Cannabinoids and viral infections. Pharmaceuticals (Basel), 2010; 3(6):1873–1886.
28.
TindallB, CooperDA, DonovanB, et al.: The Sydney AIDS Project: Development of acquired immunodeficiency syndrome in a group of HIV seropositive homosexual men. Aust NZ J Med, 1988; 18(1):8–15.
29.
AbramsDI, HiltonJF, LeiserRJ, et al.: Short-term effects of cannabinoids in patients with HIV-1 infection: A randomized, placebo-controlled clinical trial. Ann Intern Med, 2003; 139(4):258–266.
30.
MolinaPE, AmedeeA, LeCapitaineNJ, et al.: Cannabinoid neuroimmune modulation of SIV disease. J Neuroimmune Pharmacol, 2011; 6(4):516–527.
31.
MolinaPE, WinsauerP, ZhangP, et al.: Cannabinoid administration attenuates the progression of simian immunodeficiency virus. AIDS Res Hum Retroviruses, 2011; 27(6):585–592.
32.
MolinaPE, AmedeeAM, LecapitaineNJ, et al.: Modulation of gut-specific mechanisms by chronic delta9-THC administration in male rhesus macaques infected with simian immunodeficiency virus: A systems biology analysis. AIDS Res Hum Retroviruses, 2014; 30(6):567–578.
33.
Substance Abuse and Mental Health Services Administration: Results from the 2004 National Survey on Drug Use and Health: National Findings NSDUH Series H-36, HHS Publication No. SMA 09-4434 ed. Office of Applied Studies, Rockville, MD, 2005.
34.
National Institute of Justice, ADAMP: Drug and Alcohol Use & Related Matters Among Arrestees, 2003. U.S. Department of Justice, Washington, DC, 2003.
35.
Substance Abuse and Mental Health Services Administration, Synectics for Management Decisions, Inc., U.S. Department of Health and Human Services: Treatment Episode Data Set (TEDS) Series. Ann Arbor, MI, 2009.
36.
FattoreL and FrattaW: How important are sex differences in cannabinoid action?. Br J Pharmacol, 2010; 160(3):544–548.
37.
DanielJM, WinsauerPJ, BraunerIN, et al.: Estrogen improves response accuracy and attenuates the disruptive effects of delta9-THC in ovariectomized rats responding under a multiple schedule of repeated acquisition and performance. Behav Neurosci, 2002; 116(6):989–998.
38.
WinsauerPJ, DanielJM, FilipeanuCM, et al.: Long-term behavioral and pharmacodynamic effects of delta-9-tetrahydrocannabinol in female rats depend on ovarian hormone status. Addict Biol, 2011; 16(1):64–81.
39.
MizeAL and AlperRH: Acute and long-term effects of 17beta-estradiol on G(i/o) coupled neurotransmitter receptor function in the female rat brain as assessed by agonist-stimulated [35S]GTPgammaS binding. Brain Res, 2000; 859(2):326–333.
40.
RiebeCJ, HillMN, LeeTT, et al.: Estrogenic regulation of limbic cannabinoid receptor binding. Psychoneuroendocrinology, 2010; 35(8):1265–1269.
41.
GonzalezS, BisognoT, WengerT, et al.: Sex steroid influence on cannabinoid CB(1) receptor mRNA and endocannabinoid levels in the anterior pituitary gland. Biochem Biophys Res Commun, 2000; 270(1):260–266.
42.
Rodriguez de FonsecaF, CebeiraM, RamosJA, et al.: Cannabinoid receptors in rat brain areas: Sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement. Life Sci, 1994; 54(3):159–170.
43.
FilipeanuCM, GuidryJJ, LeonardST, et al.: Delta9-THC increases endogenous AHA1 expression in rat cerebellum and may modulate CB1 receptor function during chronic use. J Neurochem, 2011; 118(6):1101–1112.
44.
LeCapitaineNJ, ZhangP, WinsauerP, et al.: Chronic delta-9-tetrahydrocannabinol administration increases lymphocyte CXCR4 expression in rhesus macaques. J Neuroimmune Pharmacol, 2011; 6(4):540–545.
45.
SemanAL, PewenWF, FreshLF, et al.: The replicative capacity of rhesus macaque peripheral blood mononuclear cells for simian immunodeficiency virus in vitro is predictive of the rate of progression to AIDS in vivo. J Gen Virol, 2000; 81(Pt 10):2441–2449.
46.
FairfieldKM, EisenbergDM, DavisRB, et al.: Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients. Arch Intern Med, 1998; 158(20):2257–2264.
47.
D'SouzaG, MatsonPA, GradyCD, et al.: Medicinal and recreational marijuana use among HIV-infected women in the Women's Interagency HIV Study (WIHS) cohort, 1994–2010. J Acquir Immune Defic Syndr, 2012; 61(5):618–626.
48.
PopeHGJr, JacobsA, MialetJP, et al.: Evidence for a sex-specific residual effect of cannabis on visuospatial memory. Psychother Psychosom, 1997; 66(4):179–184.
49.
CraftRM, MarusichJA, and WileyJL: Sex differences in cannabinoid pharmacology: A reflection of differences in the endocannabinoid system?. Life Sci, 2013; 92(8–9):476–481.
50.
MathewRJ, WilsonWH, and DavisR: Postural syncope after marijuana: A transcranial Doppler study of the hemodynamics. Pharmacol Biochem Behav, 2003; 75(2):309–318.
51.
HaneyM: Opioid antagonism of cannabinoid effects: Differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology, 2007; 32(6):1391–1403.
52.
PenetarDM, KouriEM, GrossMM, et al.: Transdermal nicotine alters some of marihuana's effects in male and female volunteers. Drug Alcohol Depend, 2005; 79(2):211–223.
53.
LeatherdaleST, HammondDG, KaisermanM, et al.: Marijuana and tobacco use among young adults in Canada: Are they smoking what we think they are smoking?. Cancer Causes Control, 2007; 18(4):391–397.
54.
TsengAH and CraftRM: Sex differences in antinociceptive and motoric effects of cannabinoids. Eur J Pharmacol, 2001; 430(1):41–47.
55.
BiscaiaM, MarinS, FernandezB, et al.: Chronic treatment with CP 55,940 during the peri-adolescent period differentially affects the behavioural responses of male and female rats in adulthood. Psychopharmacology, 2003; 170(3):301–308.
56.
WileyJL, O'ConnellMM, TokarzME, et al.: Pharmacological effects of acute and repeated administration of delta(9)-tetrahydrocannabinol in adolescent and adult rats. J Pharmacol Exp Therapeut, 2007; 320(3):1097–1105.
57.
GorzalkaBB and DangSS: Minireview: Endocannabinoids and gonadal hormones: Bidirectional interactions in physiology and behavior. Endocrinology, 2012; 153(3):1016–1024.
58.
LopezHH: Cannabinoid-hormone interactions in the regulation of motivational processes. Horm Behav, 2010; 58(1):100–110.
59.
MinneySM and LopezHH: Adolescent cannabinoid treatment negatively affects reproductive behavior in female rats. Pharmacol Biochem Behav, 2013; 112:82–88.
60.
KirkhamTC: Endocannabinoids in the regulation of appetite and body weight. Behaviour Pharmacol, 2005; 16(5–6):297–313.
61.
RiggsPK, VaidaF, RossiSS, et al.: A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. Brain Res, 2012; 1431:46–52.
62.
PlasseTF, GorterRW, KrasnowSH, et al.: Recent clinical experience with dronabinol. Pharmacol Biochem Behav, 1991; 40(3):695–700.
63.
KotlerDP, WangJ, and PiersonRN: Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr, 1985; 42(6):1255–1265.
64.
GrinspoonS, CorcoranC, MillerK, et al.: Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab, 1997; 82(5):1332–1337.
65.
DiazS, FarhangB, HoienJ, et al.: Sex differences in the cannabinoid modulation of appetite, body temperature and neurotransmission at POMC synapses. Neuroendocrinology, 2009; 89(4):424–440.
66.
CzajaJA: Food rejection by female rhesus monkeys during the menstrual cycle and early pregnancy. Physiol Behav, 1975; 14(5):579–587.
67.
JohnsonWG, CorriganSA, LemmonCR, et al.: Energy regulation over the menstrual cycle. Physiol Behav, 1994; 56(3):523–527.
68.
MooreJ and TrkolaA: HIV type 1 coreceptors, neutralization serotypes, and vaccine development. AIDS Res Hum Retroviruses, 1997; 13(9):733–736.
69.
EdingerAL, AmedeeA, MillerK, et al.: Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains. Proc Natl Acad Sci USA, 1997; 94(8):4005–4010.
70.
PhillipsR and AgerA: Activation of pertussis toxin-sensitive CXCL12 (SDF-1) receptors mediates transendothelial migration of T lymphocytes across lymph node high endothelial cells. Eur J Immunol, 2002; 32(3):837–847.
